Daewoong Pharmaceutical announced on the 6th that it signed a contract on the 5th at its headquarters in Gangnam-gu, Seoul, with Seeas Technology for the domestic supply of the real-time inpatient monitoring solution thynCTM. Daewoong Pharmaceutical will be responsible for domestic distribution and after-sales service (A/S), while Seeas will handle manufacturing, production, and technical support.
Lee Chang-jae, CEO of Daewoong Pharmaceutical (left), and Lee Young-shin, CEO of Sears Technology, are posing for a commemorative photo at the signing ceremony for the supply and sales contract of Think. [Photo by Daewoong Pharmaceutical]
Real-time inpatient monitoring refers to a next-generation bedside management system that allows medical staff to continuously monitor patients' conditions and respond immediately through wireless network equipment and artificial intelligence (AI) wearable diagnostic devices. It features continuous monitoring, mobility convenience, and remote diagnosis capabilities, offering advantages such as reducing gaps in patient management and improving medical staff convenience compared to traditional wired monitoring methods.
Seeas’s thynCTM is the first domestically produced real-time inpatient monitoring solution. It analyzes and manages patients' real-time biometric signals using wearable biosensors, dashboards, monitoring management applications, and AI algorithms. It can monitor overall vital signs such as electrocardiogram, body temperature, and oxygen saturation. ThynCTM also boasts high compatibility and scalability with other wearable devices, and it is expected to play a significant role in popularizing smart ward system implementation.
Lee Chang-jae, CEO of Daewoong Pharmaceutical, said, “Through the supply of thynCTM, we will increase contributions to patients, medical staff, and hospitals,” adding, “We will enable comfortable and stable inpatient care through wearable devices, fall alarm systems, and location tracking systems, and support efficient ward management for medical staff through real-time remote monitoring systems.” Lee Young-shin, CEO of Seeas Technology, also stated, “Through business agreements with Hallym University Sacred Heart Hospital, Soonchunhyang University Central Medical Center, and Hwasun Jeonnam National University Hospital, we have demonstrated effectiveness not only in cardiovascular care but also in neurology, isolation, respiratory, and oncology wards,” and explained, “We have secured superiority in clinical results comparing equivalence with existing systems.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

